Ullrich WÃ¼llner

List of Publications by Year
in descending order

190 papers	10,813 citations	30070 54 h-index	37204 96 g-index
209 all docs	209 docs citations	209 times ranked	13417 citing authors

#	Article	IF	Citations
1	PGC-1 Î±, A Potential Therapeutic Target for Early Intervention in Parkinsonâ€™s Disease. Science Translational Medicine, 2010, 2, 52ra73.	12.4	691
2	Rapamycin alleviates toxicity of different aggregate-prone proteins. Human Molecular Genetics, 2006, 15, 433-442.	2.9	618
3	Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naÃ¯ve Parkinsonâ€™s disease patients. Genome Medicine, 2017, 9, 39.	8.2	420
4	Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Scientific Reports, 2013, 3, 3440.	3.3	383
5	Methylation Regulates Alpha-Synuclein Expression and Is Decreased in Parkinson's Disease Patients' Brains. Journal of Neuroscience, 2010, 30, 6355-6359.	3.6	364
6	Excitation-induced ataxin-3 aggregation in neurons from patients with Machadoâ€“Joseph disease. Nature, 2011, 480, 543-546.	27.8	282
7	SNCA variants are associated with increased risk for multiple system atrophy. Annals of Neurology, 2009, 65, 610-614.	5.3	257
8	Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Movement Disorders, 2003, 18, 659-667.	3.9	255
9	Multiple regions of Î±-synuclein are associated with Parkinson's disease. Annals of Neurology, 2005, 57, 535-541.	5.3	223
10	Induction of Nitric Oxide Synthase and Nitric Oxideâ€Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis FActorâ€Î±/Lipopolysaccharide. Journal of Neurochemistry, 1998, 71, 88-94.	3.9	186
11	Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Research, 1999, 826, 53-62.	2.2	166
12	Extracellular phosphorylation of the amyloid Î²-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease. EMBO Journal, 2011, 30, 2255-2265.	7.8	160
13	Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. NeuroReport, 1996, 7, 921-923.	1.2	149
14	Peroxisome proliferator-activated receptor gamma agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. Journal of Neuroimmunology, 1999, 100, 156-168.	2.3	146
15	Ataxin-3 Represses Transcription via Chromatin Binding, Interaction with Histone Deacetylase 3, and Histone Deacetylation. Journal of Neuroscience, 2006, 26, 11474-11486.	3.6	144
16	An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO Journal, 2006, 25, 1547-1558.	7.8	142
17	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
18	Bright light therapy in Parkinson's disease: A pilot study. Movement Disorders, 2007, 22, 1495-1498.	3.9	137

#	Article	IF	Citations
19	Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochemical and Biophysical Research Communications, 2007, 362, 734-739.	2.1	133
20	Qigong exercise for the symptoms of Parkinson's disease: A randomized, controlled pilot study. Movement Disorders, 2006, 21, 543-548.	3.9	126
21	Neuropsychological Features of Patients with Spinocerebellar Ataxia (SCA) Types 1, 2, 3, and 6. Cerebellum, 2010, 9, 433-442.	2.5	125
22	Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics, 2012, 13, 87-91.	1.4	122
23	Structural and functional analysis of ataxin-2 and ataxin-3. FEBS Journal, 2004, 271, 3155-3170.	0.2	118
24	Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathologica Communications, 2015, 3, 75.	5.2	115
25	Inflammatory Genes Are Upregulated in Expanded Ataxin-3-Expressing Cell Lines and Spinocerebellar Ataxia Type 3 Brains. Journal of Neuroscience, 2001, 21, 5389-5396.	3.6	110
26	The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiology of Aging, 2009, 30, 731-738.	3.1	108
27	Voxel-based morphometry and voxel-based relaxometry in multiple system atrophyâ€"A comparison between clinical subtypes and correlations with clinical parameters. NeuroImage, 2007, 36, 1086-1095.	4.2	103
28	Cooperative Interception of Neuronal Apoptosis by BCLâ€2 and BAGâ€1 Expression: Prevention of Caspase Activation and Reduced Production of Reactive Oxygen Species. Journal of Neurochemistry, 1997, 69, 2075-2086.	3.9	94
29	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death and Differentiation, 1998, 5, 847-857.	11.2	93
30	Cell death and apoptosis regulating proteins in Parkinson's disease - a cautionary note. Acta Neuropathologica, 1999, 97, 408-412.	7.7	92
31	Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability. Neurobiology of Disease, 2008, 32, 521-527.	4.4	92
32	Variants associated with Gaucher disease in multiple system atrophy. Annals of Clinical and Translational Neurology, 2015, 2, 417-426.	3.7	90
33	Dopamine Transporter Positron Emission Tomography in Spinocerebellar Ataxias Type 1, 2, 3, and 6. Archives of Neurology, 2005, 62, 1280.	4.5	89
34	CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Human Molecular Genetics, 2009, 18, 3334-3343.	2.9	88
35	Î±-Synuclein in Parkinsonâ€™s disease: causal or bystander?. Journal of Neural Transmission, 2019, 126, 815-840.	2.8	88
36	FOXO4-dependent upregulation of superoxide dismutase-2 in response to oxidative stress is impaired in spinocerebellar ataxia type 3. Human Molecular Genetics, 2011, 20, 2928-2941.	2.9	87

#	Article	IF	Citations
37	New mutations in protein kinase CÎ³ associated with spinocerebellar ataxia type 14. Annals of Neurology, 2005, 58, 720-729.	5.3	85
38	Lâ€dopa increases Î±â€synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro. Movement Disorders, 2015, 30, 1794-1801.	3.9	81
39	Genes associated with Parkinson syndrome. Journal of Neurology, 2008, 255, 8-17.	3.6	78
40	<scp>DNA</scp> methylation in Parkinson's disease. Journal of Neurochemistry, 2016, 139, 108-120.	3.9	78
41	Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinsonâ€™s disease. Cell Reports, 2021, 34, 108807.	6.4	77
42	Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease (KNP e.V.): the effect of ageing. European Journal of Neurology, 2007, 14, 1405-1408.	3.3	74
43	Gene Expression Profiling in Ataxin-3 Expressing Cell Lines Reveals Distinct Effects of Normal and Mutant Ataxin-3. Journal of Neuropathology and Experimental Neurology, 2003, 62, 1006-1018.	1.7	72
44	Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3). Human Molecular Genetics, 2013, 22, 508-518.	2.9	70
45	High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Human Molecular Genetics, 1999, 8, 1169-1176.	2.9	69
46	Differential effects of l-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Neuroscience Letters, 1999, 264, 1-4.	2.1	69
47	Alphaâ€synuclein and Parkinson's disease: Implications from the screening of more than 1,900 patients. Movement Disorders, 2005, 20, 1191-1194.	3.9	67
48	Cell death in polyglutamine diseases. Cell and Tissue Research, 2000, 301, 189-204.	2.9	66
49	Advanced glycation end products and protein carbonyl levels in plasma reveal sex-specific differences in Parkinson's and Alzheimer's disease. Redox Biology, 2020, 34, 101546.	9.0	66
50	The Machadoâ€“Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53. PLoS Biology, 2016, 14, e2000733.	5.6	66
51	Probable multiple system atrophy in a German family. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 924-925.	1.9	64
52	Smoking upregulates Î±4Î²2* nicotinic acetylcholine receptors in the human brain. Neuroscience Letters, 2008, 430, 34-37.	2.1	64
53	Transdermal rotigotine for the perioperative management of Parkinsonâ€™s disease. Journal of Neural Transmission, 2010, 117, 855-859.	2.8	64
54	The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Movement Disorders, 2008, 23, 599-602.	3.9	61

#	Article	IF	Citations
55	A Rare Truncating Mutation in ADH1C (G78Stop) Shows Significant Association With Parkinson Disease in a Large International Sample. Archives of Neurology, 2005, 62, 74.	4.5	57
56	Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells. Neurobiology of Disease, 2006, 23, 725-730.	4.4	55
57	Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 331-341.	3.2	55
58	Cognitive decline in Parkinsonâ€™s disease: the impact of the motor phenotype on cognition. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 171-179.	1.9	54
59	MPP+ Inhibits Proliferation of PC12 Cells by a p21WAF1/Cip1-Dependent Pathway and Induces Cell Death in Cells Lacking p21WAF1/Cip1. Experimental Cell Research, 1999, 250, 75-85.	2.6	50
60	Olfactory fMRI in Patients with Parkinson's Disease. Frontiers in Integrative Neuroscience, 2010, 4, 125.	2.1	50
61	The molecular biology of the autosomal-dominant cerebellar ataxias. Movement Disorders, 2000, 15, 604-612.	3.9	49
62	Bellâ€™s palsy. Journal of Neurology, 2008, 255, 1726-1730.	3.6	49
63	Spinocerebellar ataxia type 15: diagnostic assessment, frequency, and phenotypic features. Journal of Medical Genetics, 2011, 48, 407-412.	3.2	49
64	A stably self-renewing adult blood-derived induced neural stem cell exhibiting patternability and epigenetic rejuvenation. Nature Communications, 2018, 9, 4047.	12.8	49
65	Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinsonâ€™s disease. Journal of Neural Transmission, 2007, 114, 1161-1165.	2.8	48
66	Spinocerebellar ataxia type 11 (SCA11) is an uncommon cause of dominant ataxia among French and German kindreds. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1229-1232.	1.9	47
67	Parkinsonâ€™s Disease and Dementia: A Longitudinal Study (DEMPARK). Neuroepidemiology, 2011, 37, 168-176.	2.3	47
68	Epigenome-wide DNA methylation analysis in siblings and monozygotic twins discordant for sporadic Parkinsonâ€™s disease revealed different epigenetic patterns in peripheral blood mononuclear cells. Neurogenetics, 2017, 18, 7-22.	1.4	47
69	Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinsonâ€™s disease. Neuroscience, 2014, 258, 385-400.	2.3	44
70	Transcriptional changes in multiple system atrophy and Parkinson's disease putamen. Experimental Neurology, 2006, 199, 465-478.	4.1	43
71	Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. Neurochemistry International, 2000, 36, 489-497.	3.8	41
72	Parkinsonâ€™s disease influences the perioperative risk profile in surgery. Langenbeck's Archives of Surgery, 2009, 394, 511-515.	1.9	41

#	Article	IF	Citations
73	Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Movement Disorders, 2004, 19, 705-707.	3.9	40
74	The competitive NMDA antagonist CGP40.116 enhances L-DOPA response in MPTP-treated marmosets. Neuropharmacology, 1992, 31, 713-715.	4.1	39
75	Putamen dopamine transporter and glucose metabolism are reduced in SCA17. Annals of Neurology, 2005, 58, 490-491.	5.3	39
76	DNA methylation alterations in iPSC- and hESC-derived neurons: potential implications for neurological disease modeling. Clinical Epigenetics, 2018, 10, 13.	4.1	39
77	Progressive cognitive dysfunction in spinocerebellar ataxia type 3. Movement Disorders, 2013, 28, 1435-1438.	3.9	36
78	Systemic Thrombolysis for Ischemic Stroke after Antagonizing Dabigatran with Idarucizumabâ€"A Case Report. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, e126-e127.	1.6	36
79	Inflammation in Parkinson's disease. Journal of Neurology, 2003, 250, i35-i38.	3.6	35
80	Mechanical Thrombectomy Compared to Local-Intraarterial Thrombolysis in Carotid T and Middle Cerebral Artery Occlusions. Clinical Neuroradiology, 2012, 22, 141-147.	1.9	35
81	Inhibition of Thioredoxin reductase induces apoptosis in neuronal cell lines: Role of glutathione and the MKK4/JNK pathway. Biochemical and Biophysical Research Communications, 2007, 359, 759-764.	2.1	34
82	Stochastic resonance therapy in Parkinson's disease. NeuroRehabilitation, 2011, 28, 353-358.	1.3	33
83	Flupirtine and retigabine prevent l-glutamate toxicity in rat pheochromocytoma PC 12 cells. European Journal of Pharmacology, 2000, 400, 155-166.	3.5	32
84	Nuclear Aggregation of Polyglutamine-expanded Ataxin-3. Journal of Biological Chemistry, 2010, 285, 6532-6537.	3.4	32
85	Structural modeling of ataxin-3 reveals distant homology to adaptins. Proteins: Structure, Function and Bioinformatics, 2002, 50, 355-370.	2.6	31
86	Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Applied Radiation and Isotopes, 2004, 61, 1235-1240.	1.5	31
87	Much ado about nothing? Off-target amplification can lead to false-positive bacterial brain microbiome detection in healthy and Parkinsonâ€™s disease individuals. Microbiome, 2021, 9, 75.	11.1	31
88	A Randomized Pilot Study of Stochastic Vibration Therapy in Spinocerebellar Ataxia. Cerebellum, 2014, 13, 237-242.	2.5	30
89	Mutational Landscape of the BAP1 Locus Reveals an Intrinsic Control to Regulate the miRNA Network and the Binding of Protein Complexes in Uveal Melanoma. Cancers, 2019, 11, 1600.	3.7	30
90	?-Aminovaleric acid antagonizes the pharmacological actions of baclofen in the central nervous system. Experimental Brain Research, 1988, 70, 618-26.	1.5	29

#	Article	IF	Citations
91	PDON: Parkinsonâ€™s disease ontology for representation and modeling of the Parkinsonâ€™s disease knowledge domain. Theoretical Biology and Medical Modelling, 2015, 12, 20.	2.1	29
92	Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study. Alzheimer's and Dementia, 2020, 16, 292-304.	0.8	29
93	Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: The effects of 3-acetylpyridine neurotoxicity. Neuroscience, 1997, 81, 721-734.	2.3	28
94	Feasibility of [18F]-2-Fluoro-A85380-PET Imaging of Human Vascular Nicotinic Acetylcholine Receptors In Vivo. JACC: Cardiovascular Imaging, 2012, 5, 528-536.	5.3	28
95	No association of GBA mutations and multiple system atrophy. European Journal of Neurology, 2013, 20, e61-2.	3.3	28
96	5-methylcytosine and 5-hydroxymethylcytosine in brains of patients with multiple system atrophy and patients with Parkinsonâ€™s disease. Journal of Chemical Neuroanatomy, 2019, 96, 41-48.	2.1	28
97	Bcl-2, Bax and Bcl-x expression in neuronal apoptosis: a study of mutant weaver and lurcher mice. Acta Neuropathologica, 1998, 96, 233-238.	7.7	27
98	Potentiation of Treosulfan Toxicity by the Glutathione-Depleting Agent Buthionine Sulfoximine in Human Malignant Glioma Cells. Biochemical Pharmacology, 1998, 55, 349-359.	4.4	27
99	DNA Methylation of the TNF-Î± Promoter Region in Peripheral Blood Monocytes and the Cortex of Human Alzheimer's Disease Patients. Dementia and Geriatric Cognitive Disorders, 2014, 38, 10-15.	1.5	27
100	Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Movement Disorders, 2009, 24, 1080-1084.	3.9	26
101	Callosal tissue loss in multiple system atrophyâ€”A oneâ€year followâ€up study. Movement Disorders, 2010, 25, 2613-2620.	3.9	24
102	Animal Models of Uveal Melanoma: Methods, Applicability, and Limitations. BioMed Research International, 2016, 2016, 1-9.	1.9	24
103	Methylenetetrahydrofolate reductase in Parkinson's disease. Annals of Neurology, 2005, 58, 972-973.	5.3	23
104	Extensive Transcriptional Regulation of Chromatin Modifiers during Human Neurodevelopment. PLoS ONE, 2012, 7, e36708.	2.5	23
105	DNA methylation levels of Î±-synuclein intron 1 in the aging brain. Neurobiology of Aging, 2015, 36, 3334.e7-3334.e11.	3.1	23
106	Lack of genetic dispositions to hyperhomocysteinemia in Alzheimer disease. , 2004, 131A, 101-102.		22
107	Depression in Parkinsonâ€™s disease. Journal of Neurology, 2011, 258, 336-338.	3.6	22
108	Expression of the lymphatic marker podoplanin (D2-40) in human fetal eyes. Experimental Eye Research, 2014, 127, 243-251.	2.6	22

#	Article	IF	Citations
109	Apolipoprotein E Îµ4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 112-116.	2.2	22
110	MRI follow-up after magnetic resonance-guided focused ultrasound for non-invasive thalamotomy: the neuroradiologistâ€™s perspective. Neuroradiology, 2020, 62, 1111-1122.	2.2	21
111	New medical and surgical treatments for ParkinsonÊ¼s disease. Current Opinion in Neurology, 1994, 7, 346-352.	3.6	20
112	Ubiquitin Carboxyl-Terminal Hydrolases (UCHs): Potential Mediators for Cancer and Neurodegeneration. International Journal of Molecular Sciences, 2020, 21, 3910.	4.1	20
113	Altered expression of calcium- and apoptosis-regulating proteins in multiple system atrophy purkinje cells. Movement Disorders, 2000, 15, 269-275.	3.9	19
114	Variants in the 3â€²UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. European Journal of Human Genetics, 2012, 20, 1265-1269.	2.8	19
115	DJ-1 is a redox sensitive adapter protein for high molecular weight complexes involved in regulation of catecholamine homeostasis. Human Molecular Genetics, 2017, 26, 4028-4041.	2.9	19
116	The human MJD gene: genomic structure and functional characterization of the promoter region. Gene, 2003, 314, 81-88.	2.2	18
117	In vivo voxel-based relaxometry in amyotrophic lateral sclerosis. Journal of Neurology, 2009, 256, 28-34.	3.6	18
118	Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues. Journal of Neural Transmission, 2017, 124, 1029-1036.	2.8	18
119	Spatial intratumor heterogeneity in uveal melanoma: Tumor cell subtypes with a presumed invasive potential exhibit a particular epigenetic staining reaction. Experimental Eye Research, 2019, 182, 175-181.	2.6	18
120	UCHL-1 gene in multiple system atrophy: A haplotype tagging approach. Movement Disorders, 2005, 20, 1338-1343.	3.9	17
121	Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3. Experimental Neurology, 2006, 201, 182-192.	4.1	17
122	Sebaceous gland carcinoma of the ocular adnexa â€“ variability in clinical and histological appearance with analysis of immunohistochemical staining patterns. Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255, 2277-2285.	1.9	17
123	Polypharmacy in Parkinsonâ€™s disease: risks and benefits with little evidence. Journal of Neural Transmission, 2019, 126, 871-878.	2.8	17
124	Common genetic variants associated with Parkinsonâ€™s disease display widespread signature of epigenetic plasticity. Scientific Reports, 2019, 9, 18464.	3.3	17
125	Data protection in biomaterial banks for Parkinson's disease research: The model of GEPARD (Gene bank Parkinson's Disease Germany). Movement Disorders, 2007, 22, 611-618.	3.9	16
126	Transcutaneous vagal nerve stimulation improves gastroenteric complaints in Parkinsonâ€™s disease patients. NeuroRehabilitation, 2019, 45, 449-451.	1.3	16

#	Article	IF	Citations
127	Cerebrospinal Fluid Levels of Kininogenâ€1 Indicate Early Cognitive Impairment in Parkinson's Disease. Movement Disorders, 2020, 35, 2101-2106.	3.9	16
128	Gene dosage-dependent effects of bcl-2 expression on cellular survival and redox status. Free Radical Biology and Medicine, 2003, 34, 1517-1530.	2.9	15
129	Requirements for Parkinsonâ€™s disease pharmacotherapy from the patientsâ€™ perspective: a questionnaire-based survey. Current Medical Research and Opinion, 2012, 28, 1239-1246.	1.9	15
130	The patientsâ€™ perspective on the burden of idiopathic intracranial hypertension. Journal of Headache and Pain, 2021, 22, 67.	6.0	15
131	Phaclofen antagonizes the depressant effect of baclofen on spinal reflex transmission in rats. Brain Research, 1989, 496, 341-344.	2.2	14
132	Resting-state fMRI reveals increased functional connectivity in the cerebellum but decreased functional connectivity of the caudate nucleus in Parkinsonâ€™s disease. Neurological Research, 2020, 42, 62-67.	1.3	14
133	Epigenome-Wide Analysis of DNA Methylation in Parkinsonâ€™s Disease Cortex. Life, 2022, 12, 502.	2.4	14
134	Bilateral necrotizing scleritis and blindness in the myelodysplastic syndrome presumably due to relapsing polychondritis. Acta Ophthalmologica, 2000, 78, 228-231.	0.3	13
135	Elevated serum mitochondrial DNA in females and lack of altered platelet mitochondrial methylation in patients with ParkinsonÂ´s disease. International Journal of Neuroscience, 2021, 131, 279-282.	1.6	13
136	Unusual Idiopathic Lipid Keratopathy: A Newly Recognized Entity?. JAMA Ophthalmology, 2005, 123, 1435.	2.4	12
137	A Possible Genetic Link between MTHFR Genotype and Smoking Behavior. PLoS ONE, 2012, 7, e53322.	2.5	12
138	Postural Stability in Parkinsonâ€™s Disease Patients Is Improved after Stochastic Resonance Therapy. Parkinson's Disease, 2016, 2016, 1-7.	1.1	12
139	Intravitreally Injected HCmel12 Melanoma Cells Serve as a Mouse Model of Tumor Biology of Intraocular Melanoma. Current Eye Research, 2016, 41, 121-128.	1.5	11
140	Skewed X-chromosome inactivation and XIST locus methylation levels do not contribute to the lower prevalence of Parkinson's disease in females. Neurobiology of Aging, 2017, 57, 248.e1-248.e5.	3.1	11
141	Polarization and Distribution of Tumor-Associated Macrophages and COX-2 Expression in Basal Cell Carcinoma of the Ocular Adnexae. Current Eye Research, 2018, 43, 1126-1135.	1.5	11
142	Pyogenic granuloma associated with conjunctival epithelial neoplasia: report of nine cases. British Journal of Ophthalmology, 2019, 103, 1469-1474.	3.9	11
143	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. Translational Neurodegeneration, 2019, 8, 11.	8.0	10
144	Histological Corneal Alterations in Keratoconus After Crosslinkingâ€”Expansion of Findings. Cornea, 2020, 39, 333-341.	1.7	10

#	Article	IF	Citations
145	A pilot study of magnetic resonance fingerprinting in Parkinson's disease. NMR in Biomedicine, 2020, 33, e4389.	2.8	10
146	Stochastic resonance therapy induces increased movement related caudate nucleus activity. Journal of Rehabilitation Medicine, 2016, 48, 815-818.	1.1	9
147	DNA methylation of DLG4 and GJA-1 of human hippocampus and prefrontal cortex in major depression is unchanged in comparison to healthy individuals. Journal of Clinical Neuroscience, 2017, 43, 261-263.	1.5	9
148	Genome organization in proximity to the BAP1 locus appears to play a pivotal role in a variety of cancers. Cancer Science, 2020, 111, 1385-1391.	3.9	9
149	Lesions of the cerebello-thalamic tract rather than the ventral intermediate nucleus determine the outcome of focused ultrasound therapy in essential tremor: A 3T and 7T MRIâ€“study. Parkinsonism and Related Disorders, 2021, 91, 105-108.	2.2	9
150	GABAB receptors and spasticity. Trends in Pharmacological Sciences, 1990, 11, 103.	8.7	8
151	Is age-related macular degeneration associated with pinguecula or scleral plaque formation?. Current Eye Research, 2001, 23, 33-37.	1.5	8
152	Tremor in Parkinsonâ€™s disease is not associated with the DRD3 Ser9Gly polymorphism. Parkinsonism and Related Disorders, 2010, 16, 381-383.	2.2	8
153	Expanded and Wild-type Ataxin-3 Modify the Redox Status of SH-SY5Y Cells Overexpressing Î±-Synuclein. Neurochemical Research, 2017, 42, 1430-1437.	3.3	8
154	BAP1 Immunostaining in Uveal Melanoma: Potentials and Pitfalls. Ocular Oncology and Pathology, 2018, 4, 297-297.	1.0	8
155	Life style and Parkinsonâ€™s disease. Journal of Neural Transmission, 2022, 129, 1235-1245.	2.8	8
156	Epigenetic Analysis in Human Neurons: Considerations for Disease Modeling in PD. Frontiers in Neuroscience, 2019, 13, 276.	2.8	7
157	Basal cell carcinomas developing independently from BAP1â€tumor predisposition syndrome in a patient with bilateral uveal melanoma. Genes Chromosomes and Cancer, 2019, 58, 357-364.	2.8	7
158	Genes implicated in the pathogenesis of spinocerebellar ataxias. Drugs of Today, 2003, 39, 927.	2.4	7
159	Multidisciplinary management to optimize outcome of ultrasound-guided high-intensity focused ultrasound (HIFU) in patients with uterine fibroids. Scientific Reports, 2021, 11, 22768.	3.3	7
160	Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2022, 12, 905-916.	2.8	7
161	Methylation of alpha-synuclein in a Sudanese cohort. Parkinsonism and Related Disorders, 2022, 101, 6-8.	2.2	7
162	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. Movement Disorders, 2001, 16, 382-395.	3.9	6

#	Article	IF	Citations
163	TheADH1C stop mutation in multiple system atrophy patients and healthy probands in the United Kingdom and Germany. Movement Disorders, 2006, 21, 2034-2034.	3.9	6
164	DNA methylation of imprinted loci of autosomal chromosomes and IGF2 is not affected in Parkinsonâ€™s disease patientsâ€™ peripheral blood mononuclear cells. Neurological Research, 2017, 39, 281-284.	1.3	6
165	Abnormal subpopulations of monocytes in the cerebrospinal fluid of patients with Parkinson's disease. Parkinsonism and Related Disorders, 2021, 84, 144-145.	2.2	6
166	Coherent Structural and Functional Network Changes after Thalamic Lesions in Essential Tremor. Movement Disorders, 2022, 37, 1924-1929.	3.9	6
167	Regression of Periocular Basal Cell Carcinoma: A Report of Four Cases with Clinicopathologic Correlation. Ocular Oncology and Pathology, 2020, 6, 107-114.	1.0	5
168	Magnetic Resonance Imagingâ€“Guided Focused Ultrasound Thalamotomy in Spinocerebellar Ataxia Type 12. Movement Disorders, 2022, 37, 872-873.	3.9	5
169	Patient Selection for Mechanical Thrombectomy. Clinical Neuroradiology, 2014, 24, 239-244.	1.9	4
170	Impact of macrophages on tumor growth characteristics in a murine ocular tumor model. Experimental Eye Research, 2016, 151, 9-18.	2.6	4
171	Melanocytoma of the Conjunctiva: Clinicopathologic Features of Three Cases. Ocular Oncology and Pathology, 2019, 5, 290-297.	1.0	4
172	Comprehensive Profiling of Blood Coagulation and Fibrinolysis Marker Reveals Elevated Plasmin-Antiplasmin Complexes in Parkinsonâ€™s Disease. Biology, 2021, 10, 716.	2.8	4
173	Spatial and temporal immunoreaction of nestin, CD44, collagen IX and GFAP in human retinal MÃ¼ller cells in the developing fetal eye. Experimental Eye Research, 2022, 217, 108958.	2.6	4
174	Reply to: Cognitive dysfunction in spinocerebellar ataxia type 3: Variable topographies and patterns. Movement Disorders, 2014, 29, 157-158.	3.9	3
175	Preâ€•and intraretinal haemorrhages in a 22â€•weekâ€•old fetus of a mother suffering from <scp>HELLP</scp> syndrome and factor V Leiden mutation with deep vein thrombosis. Acta Ophthalmologica, 2017, 95, e83-e84.	1.1	3
176	Wound Healing of Descemet Membrane After Penetrating Keratoplasty and Its Relevance for Descemet Membrane Endothelial Keratoplasty Surgeons. Cornea, 2021, 40, 910-913.	1.7	3
177	PPAR-Responsive Elements Enriched with Alu Repeats May Contribute to Distinctive PPARÎ³â€“DNMT1 Interactions in the Genome. Cancers, 2021, 13, 3993.	3.7	2
178	Depression in Patients with Spinocerebellar Ataxia Type 3 (SCA3). Cerebellum, 2010, 9, 606-607.	2.5	1
179	Distinct patterns of cognitive impairment in multiple system atrophy patients of cerebellar and parkinsonian predominance. Basal Ganglia, 2012, 2, 91-96.	0.3	1
180	The relevance of imaging for the diagnosis of Parkinson's disease. Basal Ganglia, 2014, 4, 25-27.	0.3	1

#	Article	IF	Citations
181	Lymphatic markers in the human optic nerve: A previous study on podoplanin immunostaining in fetal eyes did not describe lymphatics in the dura mater. Experimental Eye Research, 2018, 176, 266.	2.6	1
182	Epigenetic and gene expression changes of neuronal cells from MSA patients are pronounced in enzymes for cell metabolism and calcium-regulated protein kinases. Acta Neuropathologica, 2021, 142, 781-783.	7.7	1
183	Activators of alpha synuclein expression identified by reporter cell line-based high throughput drug screen. Scientific Reports, 2021, 11, 19857.	3.3	1
184	Mechanisms of cell death in cerebellar disorders. Restorative Neurology and Neuroscience, 1998, 13, 69-73.	0.7	1
185	Genes implicated in the pathogenesis of spinocerebellar ataxias. Drugs of Today, 2003, 39, 927-37.	1.1	1
186	Cognitive deficits in multiple system atrophy (MSA): Comparison with sporadic adult onset ataxias of unknown aetiology (SAOA) and longitudinal decline. Journal of the Neurological Sciences, 2013, 333, e86.	0.6	0
187	Epigenome-wide DNA methylation analysis in brothers and monozygotic twins discordant for Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, e172.	2.2	0
188	Epigenome-wide DNA methylation analysis in brothers and monozygotic twins discordant for Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2016, 22, e86.	2.2	0
189	Response to â€œBAP1 Germline Mutation Associated with Bilateral Primary Uveal Melanomaâ€• Ocular Oncology and Pathology, 2021, 7, 1-2.	1.0	0
190	The Ratio of Expanded to Normal Ataxin 3 in Peripheral Blood Mononuclear Cells Correlates with the Age at Onset in Spinocerebellar Ataxia Type 3. Movement Disorders, 2022, 37, 1098-1099.	3.9	0